Drug Profile
Tizanidine intranasal - MDM SpA
Alternative Names: Tizanidine nasal spray - MDM SpA; TizasprayLatest Information Update: 05 Sep 2017
Price :
$50
*
At a glance
- Originator MDM SpA
- Class Antispastics; Benzothiazoles; Imidazolidines; Imidazolines; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Back pain
Most Recent Events
- 05 Sep 2017 Tizanidine intranasal is still in phase III development for Back pain in Italy (NCT02934061) (EudraCT2014-003040-12)
- 01 Feb 2017 MDM SpA completes a phase III trial in Back pain in Italy (Intranasal) (NCT02934061)